Amgen Inc. (AMGN)
Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis
AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Why Is Amgen (AMGN) Up 8% Since Last Earnings Report?
Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?
Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
AMGN Up Almost 16% in a Month: Should You Buy, Sell or Hold the Stock?
Amgen's nearly 16% surge follows strong Q3 results, raised sales guidance and growing momentum across key drugs and biosimilars.
Here's Why Amgen (AMGN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen: Buy This Cheap Biotech Leader
Amgen is a biotech leader with strong sales growth, key products outperforming, and an impressive R&D pipeline fueling future prospects. Despite political headwinds and margin pressures, AMGN raised full-year guidance and is implying resilient bottom-line growth. The stock trades at a significant valuation discount to sector peers, making AMGN an attractive value play in the current environment.
Amgen Stock: New All-Time Highs Ahead After Earnings Beat
Amgen Inc. NASDAQ: AMGN just delivered a strong beat-and-raise quarter. That's pushed the stock to within striking distance of its 52-week high.
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
